Endostatin Adenovirus With Checkpoint Inhibitor in Advanced Head and Neck or Esophageal Cancer

Launched by SICHUAN UNIVERSITY ·

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment approach for people with advanced head and neck cancer or a type of esophageal cancer called esophageal squamous cell carcinoma. The treatment involves injecting a special medicine called recombinant human endostatin adenovirus directly into the tumor, combined with another medicine that helps the immune system fight cancer, known as a PD-1 inhibitor. The main goal of this early-phase study is to see if this combination is safe, how well patients tolerate it, and whether it shows any signs of helping control the cancer.

People who might be eligible for this trial include adults with recurring or spreading head and neck cancer or those with esophageal cancer that has spread to nearby lymph nodes. Both men and women can participate, and the study is not yet open for recruiting patients. If you take part, you can expect to receive the treatment through injections into the tumor and be closely monitored by the medical team to check for side effects and how your cancer responds. This trial is an important step in finding new options for patients with these challenging cancers.

Gender

ALL

Eligibility criteria